XML 28 R7.htm IDEA: XBRL DOCUMENT v3.23.1
CONSOLIDATED CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
shares in Millions, $ in Millions
Total
Total Edwards Lifesciences, Inc. Stockholders' Equity
Common Stock
Treasury Stock
Additional Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Loss
Noncontrolling Interest
Common stock, beginning balance (in shares) at Dec. 31, 2021     642.0          
Beginning balance at Dec. 31, 2021 $ 5,835.9   $ 642.0 $ (2,416.9) $ 1,700.4 $ 6,068.1 $ (157.7)  
Treasury stock, beginning balance (in shares) at Dec. 31, 2021       17.9        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income 373.6         373.6    
Other comprehensive loss, net of tax (28.9)           (28.9)  
Common stock issued under stock plans (in shares)     0.9          
Common stock issued under stock plans 37.5   $ 0.9   36.6      
Stock-based compensation expense 32.4       32.4      
Purchases of treasury stock (in shares)       3.6        
Purchases of treasury stock (405.6)     $ (405.6)        
Common stock, ending balance (in shares) at Mar. 31, 2022     642.9          
Ending balance at Mar. 31, 2022 $ 5,844.9   $ 642.9 $ (2,822.5) 1,769.4 6,441.7 (186.6)  
Treasury stock, ending balance (in shares) at Mar. 31, 2022       21.5        
Common stock, beginning balance (in shares) at Dec. 31, 2022 608.3   646.3          
Beginning balance at Dec. 31, 2022 $ 5,806.7 $ 5,806.7 $ 646.3 $ (4,144.0) 1,969.3 7,590.0 (254.9) $ 0.0
Treasury stock, beginning balance (in shares) at Dec. 31, 2022 38.0     38.0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Net income $ 340.5 340.5       340.5    
Other comprehensive loss, net of tax (0.5) (0.5)         (0.5)  
Common stock issued under stock plans (in shares)     0.8          
Common stock issued under stock plans 41.9 41.9 $ 0.8   41.1      
Stock-based compensation expense 38.9 38.9     38.9      
Purchases of treasury stock (in shares)       3.1        
Purchases of treasury stock (249.5) (249.5)   $ (249.5)        
Changes to noncontrolling interest $ 84.0             84.0
Common stock, ending balance (in shares) at Mar. 31, 2023 606.0   647.1          
Ending balance at Mar. 31, 2023 $ 6,062.0 $ 5,978.0 $ 647.1 $ (4,393.5) $ 2,049.3 $ 7,930.5 $ (255.4) $ 84.0
Treasury stock, ending balance (in shares) at Mar. 31, 2023 41.1     41.1